Inhibrx Biosciences (INBX) Receivables - Other (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Receivables - Other for 3 consecutive years, with -$706000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables - Other fell 393.71% year-over-year to -$706000.0; the TTM figure through Dec 2025 stood at -$1.6 million (changed N/A YoY), while the FY2025 annual figure was $177000.0, up 131.27% from the prior year.
• Receivables - Other slipped to -$706000.0 in Q4 2025 per INBX's latest filing, from $727000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $952000.0 in Q2 2024 and bottomed at -$768000.0 in Q3 2024.
• Historically, Receivables - Other has averaged $251125.0 across 3 years, with a median of $608500.0 in 2023.
• On a YoY basis, Receivables - Other climbed as much as 194.66% in 2025 and fell as far as 393.71% in 2025.
• Inhibrx Biosciences' Receivables - Other stood at $607000.0 in 2023, then slumped by 123.56% to -$143000.0 in 2024, then tumbled by 393.71% to -$706000.0 in 2025.
• Business Quant data shows INBX's Receivables - Other at -$706000.0 in Q4 2025, $727000.0 in Q3 2025, and $730000.0 in Q2 2025.